Answers are grounded in this paper and cite their sources.
Female genital schistosomiasis (FGS) and urogenital schistosomiasis (UGS) are related but clinically distinct manifestations of Schistosoma haematobium infection in sub-Saharan Africa (SSA). FGS directly requires evidence of genital-tract involvement, whereas urine-based evidence identifies urinary, urogenital infection and does not by itself confirm FGS. This systematic review and meta-analysis primarily aimed to estimate the pooled proportion of FGS among females assessed in endemic SSA settings, summarized UGS/urinary evidence separately and the combined exploratory review of UGS and UGS with urinary evidence. The review was reported in accordance with PRISMA 2020. PubMed, Embase, Web of Science, Scopus, Google Scholar, WHO, and ESPEN sources were searched from inception to 15 July 2025. Studies reporting an assessable female population and an extractable diagnostic denominator for FGS and UGS/urinary evidence were eligible. A final study-level diagnostic audit classified direct genital-tract FGS using WHO Atlas-compatible visual findings, colposcopic examination, genital histopathology, microscopy, and molecular detection in genital specimens. Urine microscopy, filtration, sedimentation, and urine-based molecular testing without direct genital confirmation was classified as UGS/urinary evidence. The primary analysis pooled direct genital-tract FGS, the secondary analysis pooled UGS/urinary evidence, and the combined 22-study estimate was treated as exploratory. Proportions were pooled in R version 4.5.3 using meta version 8.5-0 and a random-intercept logistic generalized linear mixed model with a logit transformation. Heterogeneity was assessed using I², τ², and 95% prediction intervals and explored through subgroup analyses, meta-regression, and a leave-one-out sensitivity analysis. Twenty-two studies comprising 8,280 female participants were included. Following the final diagnostic audit, 12 studies contributed direct genital-tract FGS evidence and 10 contributed UGS/urinary evidence. The primary analysis of direct genital-tract FGS yielded a pooled proportion of 36% (95% CI: 23%–50%), with substantial between-study heterogeneity (τ² = 1.0805; I² = 96.9%) and a 95% prediction interval of approximately 5%–86%. The secondary UGS/urinary-evidence analysis yielded a pooled proportion of 19% (95% CI: 9%–35%), also with very high heterogeneity (τ² = 1.7153; I² = 98.8%) and a 95% prediction interval of approximately 1%–84%. An exploratory synthesis combining all 22 studies yielded a pooled proportion of approximately 27.0% (95% CI: 18.0%–39.0%), with τ² = 1.5451 and I² = 98.4%. Self-reported symptoms included vaginal discharge (35.0%), vaginal bleeding (23.0%), hematuria (19.0%), and dyspareunia (32.0%). Objectively assessed genital signs included homogeneous yellow sandy patches (30.0%), gray sandy patches (30.0%), abnormal blood vessels (14.0%), and rubbery papules (4.0%). Leave-one-out estimates for the primary FGS analysis ranged from 33.1% to 40.4%, indicating that no single direct-FGS study materially changed the pooled estimate. Direct genital-tract FGS was identified in a substantial proportion of females assessed in the included endemic SSA study populations, but heterogeneity was high and the estimate should not be interpreted as general-population prevalence. UGS/urinary evidence was lower and was analyzed separately because urine-based testing does not confirm FGS. The combined 22-study estimate is an exploratory review-wide summary rather than a disease-specific burden estimate. Standardized genital-tract diagnosis, integration of FGS awareness and referral into reproductive health services, and clear reporting of diagnostic denominators remain priorities.
No takes yet. Share an insight, caveat, or question.
Gebremedhn et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: